Using apixaban (Eliquis; Bristol-Myers Squibb) for the treatment of atrial fibrillation (AF) is associated with significantly less gastrointestinal bleeding when compared with other direct oral ...
For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...
In A-fib patients selected using established dose-reduction criteria, the 2.5-mg twice daily dose of apixaban (Eliquis; Bristol-Myers Squibb) provides protection against stroke and death versus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback